Before choosing an ADT, consider the risks
Increase in
Diabetes Risk1,2
Increase in
Overall CV Risks1,2
Treatment with LHRH agonists has been associated with additional cardiovascular events and diabetes complications in men with prostate cancer.2
The drug labels of some commonly prescribed LHRH agonists for ADT include specific warnings about the increased risks of certain cardiovascular diseases (eg, heart attack, stroke, sudden cardiac death) and diabetes.2
Not all ADTs carry these warnings.
The National Comprehensive Cancer Network® recommends screening for and intervention to prevent and treat cardiovascular disease and/or diabetes in men receiving ADT for prostate cancer2,3
Educate yourself about the potential safety issues and carefully weigh the benefits and risks of certain ADTs when choosing a treatment for your patients.
Carefully weigh the benefits and risks of certain ADTs
when determining treatment for your patients
Cardiovascular Risks4,5
- Increased blood pressure levels4
- Increased cholesterol levels4
- History of smoking5
- Elevated blood sugar levels4
- Problems maintaining a healthy weight5
Diabetes Risks6
- Elevated blood sugar levels
- Problems maintaining a healthy weight
- An unhealthy diet and a lack of exercise
EVALUATE THE RISKS
Find out more about the risk factors associated with agonists and evaluate your patients for these risks before selecting an ADT.
MORE FROM FERRING PHARMACEUTICALS
Ferring Pharmaceuticals is dedicated to Urology and Oncology. See additional information on all Ferring products.
FDA SAFETY COMMUNICATION
CV = cardiovascular; LHRH = luteinizing hormone-releasing hormone.
References: 1. Keating NL, O’Malley J, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol. 2006;24(27):4448-4456. 2. Food and Drug Administration. FDA Drug Safety Communication: update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases. https://www.fda.gov/Drugs/DrugSafety/ucm229986.htm. Accessed November 29, 2017. 3. National Comprehensive Cancer Network®. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Prostate Cancer. V2.2017. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed August 18, 2017. 4. Centers for Disease Control and Prevention. Conditions that increase risk for heart disease. https://www.cdc.gov/heartdisease/conditions.htm. Updated August 10, 2015. Accessed November 29, 2017. 5. Centers for Disease Control and Prevention. Heart disease behavior. https://www.cdc.gov/heartdisease/behavior.htm. Updated August 10, 2015. Accessed November 29, 2017. 6. Centers for Disease Control and Prevention. Managing diabetes: prevent complications. https://www.cdc.gov/diabetes/managing/problems.htm. Updated September 27, 2016. Accessed September 20, 2017.
